Revenio Group Oyj (HEL:REG1V), a health technology company focussing on ophthalmic products, announced on Monday that it has appointed Mikko Moilanen as the CEO of the company, effective on 5 August 2019.
Timo Hildén, the previous CEO, will continue to lead the integration work of CenterVue acquisition.
Previously, Moilanen was the CEO of Grano Group Oy, owned by the investment company Panostaja Oyj, He also held the position of CEO of Suunto Oy and he has held several international management positions in Nokia Plc.
Revenio Group consists of Icare Finland Oy, Icare USA Inc, Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy and Oscare Medical Oy.
Moderna and Catalent Team for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine Candidate
Akeso names new lead gynecologic oncology advisor and chair of the Steering Committee
Therapeutics Solutions International plans to use StemVacs for COVID-19 patient treatment
Clover Biopharmaceuticals Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate
Epsilen Bio Names Berretta as Chief Executive Officer and Simon as Chairman of the Board
CANbridge Pharmaceuticals appoints Carrie Ann Cook new SVP/global head of Business Development